Assessing the Value of New Antibiotics
Dr. Solà-Morales Serra has participated in the formulation of a new study called, Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions.
Dr. Solà-Morales Serra has participated in the formulation of a new study called, Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions.
Dr. Solà-Morales Serra has participated in the formulation of a new study that explains the innovative approach of drug’s public procurement.
On date 03 of May of 2017, Health innovation technology transfer has been selected by Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS).
The objective of this workshop was achieving a multistakeholder work table discussing about issues related to drugs pricing, focusing the horizon scanning, access to innovation, current and future role of insurances and private providers.
Dr. Solà-Morales was invited to give a presentation in a plenary session at the 20th National Hospital Congess (Sevilla, dates) on uses of Real World Evidence (RWE).
hitt ha participat a la jornada Lessons Learned: Market Access and Reimbursement organitzada per l’associació d’empreses CataloniaBio i Biocat el 29 de novembre al Parc Científic de Barcelona, on també s’han pogut escoltar i debatre les lliçons apreses d’altres experts consultors i de la indústria del sector.
A brief monthly report about news and facts in policy, industry, drugs and devices in the spanish and portuguese market access.
A brief monthly report about news and facts in policy, industry, drugs and devices in the spanish market access.